Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
Category: #health  By Mateen Dalal  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
  • INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.  
     
  • Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first six months of 2020.

Inhibrx Inc., an international biotechnology company founded in 2010 aimed at developing a pipeline of new biologic therapeutic candidates, reportedly announced the registration of first patient in its Phase 1 clinical trial of a therapeutic candidate INBRX-101 (NCT03815396).

NCT03815396 is a therapeutic candidate based on Fc-fusion protein which comprises improved recombinant iterations of human alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency, commonly called AATD, in patients.

AATD is a rare respiratory disease that is characterized by continuous impairment of lung tissue which leads to emphysema and COPD. Reports cite, approx. 100,000 people are affected by this disease across the United States with Europe numbers being at the same approximate level.

Plasma derived augmentation therapy (pdAAT), present standard of care of patients affected with AATD, has remained unchanged for several decades and depends on the weekly infusions of AAT derived from plasma purified from the human donor serum.

The company’s therapeutic candidate INBRX-101 is developed to provide greater clinical activity into pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.   

CEO of Inhibrx, Mark Lappe stated that the company applied its protein engineering capabilities for overcoming the challenges associated with producing functional recombinant human alpha-1 antitrypsin, apart from identifying modifications that the company believes to be capable to optimize PK functionality and profile. Mark further added that the company is thrilled to start enrollment of Phase 1 trial to assess the potential advantages of INBRX-101 in individuals affected by AATD.

Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first 6 months of 2020.

 

Source credit: https://inhibrx.com/inhibrx-announces-enrollment-of-first-patient-in-phase-1-study-of-inbrx-101-a-modified-recombinant-human-aat-fc-fusion-protein/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...